Croonenberghs J, Wauters A, Devreese K, Verkerk R, Scharpe S, Bosmans E, Egyed B, Deboutte D, Maes M. 2002. Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol Med 32(8):1457-63.


Dales L, Hammer SJ, Smith N. 2001. Time trends in autism and in MMR immunization coverage in California. JAMA 285(9):1183-5.

Daniels WW, Warren RP, Odell JD, Maciulis A, Burger RA, Warren WL, Torres AR. 1995. Increased frequency of the extended or ancestral haplotype B44-SC30-DR4 in autism. Neuropsychobiology 32(3):120-3.

Davidovitch M, Glick L, Holtzman G, Tirosh E, Safir MP. 2000. Developmental regression in autism: maternal perception. J Autism Dev Disord 30(2):113-9.

Davis R. 2004. Presentation to the Immunization Safety Review. Review of ‘Safety of Thimerosal-Containing Vaccines: a Two Phased Study of Computerized Health Maintenance Organization Databases.’ Washington, DC.

DelGiudice-Asch G, Simon L, Schmeidler J, Cunningham-Rundles C, Hollander E. 1999. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord 29(2):157-60.

DeStefano F, Bhasin TK, Thompson WW, Yeargin-Allsopp M, Boyle C. 2004. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics 113(2):259-66.

DeWilde S, Carey IM, Richards N, Hilton SR, Cook DG. 2001. Do children who become autistic consult more often after MMR vaccination? British J Gen Pract. 51(464):226-7.

Dickersin K, Braun L, Mead M, Millikan R, Wu AM, Pietenpol J, Troyan S, Anderson B, Visco F. 2001. Development and implementation of a science training course for breast cancer activists: Project LEAD (leadership, education and advocacy development). Health Expect 4(4):213-20.


Evans H. 1998. Mercury. Environmental and Occupational Medicine. 3rd ed. Philadelphia: Lippincott-Raven.

Evers M, Cunningham-Rundles C, Hollander E. 2002. Heat shock protein 90 antibodies in autism. Mol Psychiatry 7(Suppl 2):S26-8.


Farrington CP, Miller E, Taylor B. 2001. MMR and autism: further evidence against a causal association. Vaccine 19(27):3632-5.

Fatemi SH, Halt AR, Stary JM, Realmuto GM, Jalali-Mousavi M. 2001. Reduction in anti-apoptotic protein Bcl-2 in autistic cerebellum. Neuroreport 12(5):929-33.

FDA (Food and Drug Administration). 2001. Thimerosal content in some currently manufactured U.S. licensed vaccines (table). Accessed July, 2001. Web Page. Available at: http://www.fda.gov/cber/vaccine/thimcnt.htm.

FDA. 2004a. VAERS reports of autism. (Email communication from Jane Woo, Food and Drug Administration, March 31, 2004.)

FDA. 2004b. VAERS reports of autism. (Email communication from Jane Woo, Food and Drug Administration, March 2, 2004.)

FDA. 2004c. VAERS reports of autism. (Email communication from Jane Woo, Food and Drug Administration, March 8, 2004.)

FDA. 2004d. Table 1: Technical Review. (E-mail communication from William Egan, Food and Drug Administration, May 11, 2004.)

FDA. 2004e. Thimerosal content in vaccines. (Email communication from Karen Midthun, Food and Drug Administration, May 7, 2004.)

Filipek PA, Accardo PJ, Baranek GT, Cook EH, Dawson G, Gordon B, Gravel JS, Johnson CP, Kallen RJ, Levy SE, Minshew NJ, Ozonoff S, Prizant BM, Rapin I, Rogers SJ, Stone WL, Teplin S, Tuchman RF, Volkmar FR. 1999. The screening and diagnosis of autistic spectrum disorders. J Autism Dev Disord 29(6):439-84.

Fiumara A, Sciotto A, Barone R, D’Asero G, Munda S, Parano E, Pavone L. 1999. Peripheral lymphocyte subsets and other immune aspects in Rett syndrome. Pediatr Neurol 21(3):619-21.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement